DGX — Quest Diagnostics Incorporated stock price, charts and financials
QT66Quest Diagnostics IncorporatedQuest Diagnostics Incorporated (NYSE: DGX) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 26.27 | EPS (ttm) | 9.42 | Insider Own | 1.06% | Shs Outstand | 110.37M | Perf Week | 7.06% |
| Market Cap | 27.31B | Forward P/E | 20.52 | EPS next Y | 12.06 | Insider Trans | -4.47% | Shs Float | 109.84M | Perf Month | 4.74% |
| Enterprise Value | 33.07B | PEG | 3.61 | EPS next Q | 2.85 | Inst Own | - | Short Float | 3.14% | Perf Quarter | 25.13% |
| Income | 1.06B | P/S | 2.36 | EPS this Y | 18.81% | Inst Trans | - | Short Ratio | 3.66 | Perf Half Y | 26.75% |
| Sales | 11.56B | P/B | 3.49 | EPS next Y | 7.74% | ROA | 6.27% | Short Interest | 3.45M | Perf YTD | 42.60% |
| Book/sh | 70.84 | P/C | 43.63 | EPS next 5Y | 7.27% | ROE | 14.49% | 52W High | 248.69 -0.50% | Perf Year | 37.35% |
| Cash/sh | 5.67 | P/FCF | 21.26 | EPS past 3/5Y | 3.12% -3.62% | ROIC | 8.25% | 52W Low | 171.17 44.56% | Perf 3Y | 94.49% |
| Dividend Est. | 3.44 (1.39%) | EV/EBITDA | 16.47 | Sales past 3/5Y | 3.74% 3.18% | Gross Margin | 33.15% | Volatility | 2.40% 2.18% | Perf 5Y | 57.26% |
| Dividend TTM | 3.32 (1.34%) | EV/Sales | 2.86 | EPS Y/Y TTM | 22.50% | Oper. Margin | 14.14% | ATR (14) | 5.34 | Perf 10Y | 193.67% |
| Dividend Ex-Date | Oct 06, 2026 | Quick Ratio | 1.46 | Sales Y/Y TTM | 17.10% | Profit Margin | 9.19% | RSI (14) | 65.00 | Recom | 2.71 |
| Dividend Gr. 3/5Y | -1.14% 7.35% | Current Ratio | 1.59 | EPS Q/Q | 19.08% | SMA20 | 2.74% | Beta | 0.53 | Target Price | 246.67 |
| Payout | 34.18% | Debt/Eq | 0.95 | Sales Q/Q | 10.21% | SMA50 | 6.72% | Rel Volume | 1.02 | Prev Close | 247.08 |
| Employees | 51,500 | LT Debt/Eq | 0.86 | Earnings | Oct 20 | SMA200 | 21.83% | Avg Volume | 967.50K | Price | 247.45 |
| IPO Date | Dec 17, 1996 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 10.53% 2.36% | Net Debt/EBITDA | 2.87 | Volume | 989,467 | Change | 0.15% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-08-26 | Reiterated | UBS | Neutral | $232 → $245 |
| Jul-29-26 | Reiterated | Argus Research | Buy | $225 → $260 |
| Jul-24-26 | Reiterated | Robert W. Baird | $236 → $255 | |
| Jul-24-26 | Reiterated | UBS | Neutral | $210 → $232 |
| Jul-23-26 | Reiterated | Jefferies | Buy | $225 → $245 |
| Jul-13-26 | Reiterated | Robert W. Baird | $232 → $236 | |
| Apr-21-26 | Reiterated | Evercore ISI | In Line | $210 → $225 |
| Apr-21-26 | Reiterated | Jefferies | Buy | $220 → $225 |
| Apr-08-26 | Reiterated | Evercore ISI Group | In Line | $220 → $210 |
| Feb-12-26 | Reiterated | Mizuho | Outperform | $210 → $235 |
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 11,560 | 11,035 | 9,872 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 7,728 | 7,512 | 6,628 | — | — | — | — | — | — | |
| Gross Profit | 3,832 | 3,523 | 3,244 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 2,020 | 1,967 | 1,770 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 177 | -47 | 128 | — | — | — | — | — | — | |
| Operating Income | 1,635 | 1,603 | 1,346 | — | — | — | — | — | — | |
| Interest Expense | 262 | 277 | 226 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 46 | 34 | 74 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,419 | 1,360 | 1,194 | — | — | — | — | — | — | |
| Income Taxes | 320 | 314 | 273 | — | — | — | — | — | — | |
| Consolidated Net Income | 1,062 | 992 | 871 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,099 | 1,046 | 921 | — | — | — | — | — | — | |
| Net Income | 1,062 | 992 | 871 | — | — | — | — | — | — | |
| EPS (Recurring) | 9.54 | 8.87 | 7.80 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 9.54 | 8.87 | 7.80 | — | — | — | — | — | — | |
| EPS (Diluted) | 9.42 | 8.75 | 7.69 | — | — | — | — | — | — | |
| EBITDA | 2,008 | 2,194 | 1,894 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 26.27 | 19.83 | 19.62 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.35 | 1.75 | 1.70 | — | — | — | — | — | — | |
| Gross Margin | 33.15 | 31.93 | 32.86 | — | — | — | — | — | — | |
| Operating Margin | 14.14 | 14.53 | 13.63 | — | — | — | — | — | — | |
| Net Margin | 9.19 | 8.99 | 8.82 | — | — | — | — | — | — | |
| Shares Outstanding | 110 | 111 | 111 | — | — | — | — | — | — | |
| Market Capitalization | 27,220 | 19,262 | 16,745 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Davis J. E. | CEO and President | Sep 01 '26 | Sale | 242.72 | 10,000 | 2,427,200 | 122,423 | Sep 03 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Aug 28 '26 | Option Exercise | 112.17 | 22,677 | 2,543,679 | 60,234 | Aug 31 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Aug 28 '26 | Sale | 243.11 | 22,677 | 5,513,083 | 37,557 | Aug 31 |
| DELANEY MARK E | SVP & Chief Commercial Officer | Jul 28 '26 | Sale | 235.18 | 1,600 | 376,288 | 10,335 | Jul 29 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Jun 04 '26 | Option Exercise | 124.22 | 8,147 | 1,012,000 | 21,657 | Jun 08 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Jun 04 '26 | Sale | 200.00 | 8,147 | 1,629,400 | 13,510 | Jun 08 |
| Davis J. E. | CEO and President | Jun 01 '26 | Sale | 194.14 | 10,000 | 1,941,400 | 132,423 | Jun 02 |
| Plewman Patrick | SVP for Diagnostic Services | Mar 05 '26 | Sale | 206.21 | 2,855 | 588,730 | 15,198 | Mar 06 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Mar 05 '26 | Sale | 206.21 | 3,878 | 799,682 | 37,557 | Mar 06 |
| Doherty Catherine T. | EVP, Regional Businesses | Mar 05 '26 | Sale | 206.21 | 5,558 | 1,146,115 | 67,122 | Mar 06 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Mar 04 '26 | Sale | 204.86 | 2,628 | 538,372 | 13,441 | Mar 06 |
| Plewman Patrick | SVP for Diagnostic Services | Mar 03 '26 | Sale | 207.73 | 410 | 85,169 | 15,198 | Mar 04 |
| Doherty Catherine T. | EVP, Regional Businesses | Mar 03 '26 | Sale | 207.73 | 632 | 131,285 | 67,122 | Mar 04 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Mar 03 '26 | Sale | 207.73 | 526 | 109,266 | 37,557 | Mar 04 |
| Davis J. E. | CEO and President | Mar 02 '26 | Sale | 212.52 | 10,000 | 2,125,200 | 117,185 | Mar 04 |